Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 16/20 | 0.50 |
| ▸ | TOP2A | P11388 | 2/20 | 0.50 |
| ▸ | TOP2B | Q02880 | 2/20 | 0.50 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | CACNA1D | Q01668 | 1/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.48 |
| ▸ | CACNA1S | Q13698 | 1/20 | 0.48 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL501142 | 1.00 | GSK3B (0.50) | GSK3BTOP2ATOP2BCACNA1FPOLB | |
| SCHEMBL4747724 | 0.93 | GSK3B (0.50) | GSK3BTOP2ATOP2BCACNA1FPOLB | |
| SCHEMBL14572392 | 0.91 | GSK3B (0.53) | GSK3BTOP2ATOP2BCACNA1FPOLB | |
| SCHEMBL5620413 | 0.89 | GSK3B (0.53) | GSK3BTOP2ATOP2BCACNA1FPOLB | |
| SCHEMBL4673103 | 0.89 | GSK3B (0.53) | GSK3BTOP2ATOP2BCACNA1FPOLB | |
| SCHEMBL8139161 | 0.89 | GSK3B (0.53) | GSK3BTOP2ATOP2BCACNA1FPOLB | |
| SCHEMBL5619172 | 0.89 | GSK3B (0.53) | GSK3BTOP2ATOP2BCACNA1FPOLB | |
| SCHEMBL4747701 | 0.86 | GSK3B (0.49) | GSK3BTOP2ATOP2BCACNA1FPOLB | |
| SCHEMBL4671582 | 0.86 | STAT3 (0.46) | GSK3BTOP2ATOP2BCACNA1FPOLB | |
| SCHEMBL500723 | 0.86 | GSK3B (0.66) | GSK3BTOP2ATOP2BCACNA1FPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0990654-B1 | SUBSTITUTED CYCLOBUTYLAMINE DERIVATIVES | DAIICHI SANKYO CO LTD (JP) | 2007-11-14 | — | — | EP | disclosed |
| US-7186843-B2 | potent antibacterial activity against various bacteria including drug-resistant strains | DAIICHI PHARMACEUTICAL CO. LTD. (JP) | 2007-03-06 | — | — | US | disclosed |
| EP-0911328-B1 | SUBSTITUTED AMINOCYCLOALKYLPYRROLIDINE DERIVATIVES | DAIICHI SEIYAKU CO (JP) | 2006-02-08 | — | — | EP | disclosed |
| EP-1134219-B1 | CYCLOALKYL-SUBSTITUTED AMINOMETHYLPYRROLIDINE DERIVATIVES | DAIICHI SEIYAKU CO (JP) | 2005-06-15 | — | — | EP | disclosed |
| EP-1020459-B1 | CIS-DISUBSTITUTED AMINOCYCLOALKYL-PYRROLIDINE DERIVATIVES | DAIICHI SEIYAKU CO (JP) | 2005-04-06 | — | — | EP | disclosed |
| US-20040209940-A1 | Aminomethylpyrrolidine derivatives having aromatic substituents | DAIICHI PHARMACEUTICAL CO., LTD. | 2004-10-21 | — | — | US | disclosed |
| US-6762181-B1 | BROAD ANTIBACTERIAL ACTIVITY INCLUDING DRUG RESISTANT STAPHYLOCOCCUS AUREUS (MRSA), PNEUMOCOCCUS (PRSP) AND ENTEROCOCCUS (VRE); SAFELY USED IN CONJUCTION WITH NONSTEROIDAL ANTIINFLAMMATORY DRUGS | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-07-13 | — | — | US | disclosed |
| EP-1182202-B1 | AMINOMETHYLPYRROLIDINE DERIVATIVES HAVING AROMATIC SUBSTITUENTS | DAIICHI SEIYAKU CO (JP) | 2004-06-02 | — | — | EP | disclosed |
| EP-0947513-B1 | TRICYCLIC AMINE DERIVATIVES | DAIICHI SEIYAKU CO (JP) | 2004-05-19 | — | — | EP | disclosed |
| US-6586604-B2 | Antimicrobial activity versus gram negative and gram positive bacteria | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2003-07-01 | — | — | US | disclosed |
| US-6384050-B1 | GASTROINTESTINAL DISORDERS | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2002-05-07 | — | — | US | disclosed |
| EP-1182202-A1 | AMINOMETHYLPYRROLIDINE DERIVATIVES HAVING AROMATIC SUBSTITUENTS | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2002-02-27 | — | — | EP | disclosed |
| EP-1167344-A1 | PROCESS FOR PRODUCING 5-AMINO-8- ALKYLQUINOLO NECARBOXYLIC ACID DERIVATIVES AND INTERMEDIATES IN THE PRODUCTION THEREOF | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2002-01-02 | — | — | EP | disclosed |
| US-20010037030-A1 | Tricyclic amine derivatives | TAKEMURA MAKOTO (JP) | 2001-11-01 | — | — | US | disclosed |
| US-6184388-B1 | ANTIBACTERIAL AND ANTIMICROBIAL, QUINOLINE ANTIBIOTIC | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2001-02-06 | — | — | US | disclosed |
| US-6121285-A | 5-AMINO-7-(4-(1-AMINOCYCLOPROPYL-3-FLUORO-1-PYRROLIDINYL)-6 -FLUORO-1-(2-FLUORO-1-CYCLOPROPYL)-1,4-DIHYDRO-8-METHOXY-4-OXOQUINOLINE-3 -CARBOXYLIC ACID, FOR EXAMPLE; ANTIMICROBIAL DRUGS WITH HIGH SAFETY | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2000-09-19 | — | — | US | disclosed |
| EP-1020459-A1 | CIS-DISUBSTITUTED AMINOCYCLOALKYL-PYRROLIDINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2000-07-19 | — | — | EP | disclosed |
| EP-0990654-A1 | SUBSTITUTED CYCLOBUTYLAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2000-04-05 | — | — | EP | disclosed |
| EP-0947513-A1 | TRICYCLIC AMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 1999-10-06 | — | — | EP | disclosed |
| EP-0911328-A1 | SUBSTITUTED AMINOCYCLOALKYLPYRROLIDINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 1999-04-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010037030-A1 | Tricyclic amine derivatives | Q6ZSR9, TOP2A, TOP1 | GSK3B 2722/4885TOP2A 2/4885TOP2B 31/4885 |
| US-20040209940-A1 | Aminomethylpyrrolidine derivatives having aromatic substituents | Q6ZSR9, NAT1, NAT10 | GSK3B 4658/4885TOP2A 184/4885TOP2B 506/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.